Biolipox AB – Trademark Portfolio
Entity Type: 98
Biolipox AB has 6 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 2 are successfully registered — a 100% registration rate. The portfolio includes marks such as ZUBSOLV. Filings span 5 Nice Classification classes, with the highest activity in Class 35 (Advertising & Business) and Class 42 (Computer & Scientific).
Virdings Allé 22
SE-754 50 Uppsala
Showing of trademarks Trademarks
Trademark Classifications
Biolipox AB's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Biolipox AB have?
Biolipox AB has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Biolipox AB file in?
Biolipox AB files trademarks across 5 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 41 (Education & Entertainment), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are Biolipox AB's most well-known trademarks?
Biolipox AB's registered trademark portfolio includes well-known marks such as ZUBSOLV. These are among 2 currently registered trademarks in the portfolio.
What is Biolipox AB's trademark registration success rate?
Biolipox AB has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.